MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525680 | Name: MK-2048
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MK-2048 is a a second-generation HIV-1 integrase inhibitor. MK-2048 represents a prototype second-generation integrase strand transfer inhibitor (INSTI) developed with the goal of retaining activity against viruses containing mutations associated with resistance to first-generation INSTIs, raltegravir (RAL) and elvitegravir (EVG).

Chemical Structure

MK-2048
MK-2048
CAS#869901-69-9

Theoretical Analysis

MedKoo Cat#: 525680

Name: MK-2048

CAS#: 869901-69-9

Chemical Formula: C21H21ClFN5O4

Exact Mass: 461.1266

Molecular Weight: 461.88

Elemental Analysis: C, 54.61; H, 4.58; Cl, 7.68; F, 4.11; N, 15.16; O, 13.86

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 weeks
10mg USD 950.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MK2048; MK 2048; MK-2048
IUPAC/Chemical Name
(S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide
InChi Key
JSRREMIKIHJGAA-JTQLQIEISA-N
InChi Code
InChI=1S/C21H21ClFN5O4/c1-4-26-8-10(2)28-16-14(18(29)17(28)21(26)32)20(31)27(25-15(16)19(30)24-3)9-11-5-6-13(23)12(22)7-11/h5-7,10,29H,4,8-9H2,1-3H3,(H,24,30)/t10-/m0/s1
SMILES Code
O=C(C(C1=C2C(O)=C3N1[C@@H](C)CN(CC)C3=O)=NN(CC4=CC=C(F)C(Cl)=C4)C2=O)NC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MK-2048 is a potent inhibitor of integrase and INR263K with IC50 of 2.6 nM and 1.5 nM.
In vitro activity:
MK-2048 efficiently reduced proviral loads in primary HTLV-1 carrier PBMCs (n = 4), but had no effect on the total numbers of these cells, indicating that MK-2048 does not affect the proliferation of HTLV-1-uninfected PBMCs. MK-2048 specifically activated the ER stress-related proapoptotic gene, DNA damage-inducible transcript 3 protein (DDIT3), also known as C/EBP homologous protein (CHOP), in HTLV-1-infected but not uninfected cells of HTLV-1-carrier PBMCs. Reference: Blood Adv. 2020 May 12;4(9):1845-1858. https://pubmed.ncbi.nlm.nih.gov/32369565/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMSO 9.0 19.49
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 461.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tong X, Patel SK, Li J, Patton D, Xu E, Anderson PL, Parikh U, Sweeney Y, Strizki J, Hillier SL, Rohan LC. Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention. Polymers (Basel). 2022 Mar 16;14(6):1196. doi: 10.3390/polym14061196. PMID: 35335526; PMCID: PMC8955144. 2. Ikebe E, Matsuoka S, Tezuka K, Kuramitsu M, Okuma K, Nakashima M, Kobayashi S, Makiyama J, Yamagishi M, Oyadomari S, Uchimaru K, Hamaguchi I. Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells. Blood Adv. 2020 May 12;4(9):1845-1858. doi: 10.1182/bloodadvances.2019001139. PMID: 32369565; PMCID: PMC7218438.
In vitro protocol:
1. Tong X, Patel SK, Li J, Patton D, Xu E, Anderson PL, Parikh U, Sweeney Y, Strizki J, Hillier SL, Rohan LC. Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention. Polymers (Basel). 2022 Mar 16;14(6):1196. doi: 10.3390/polym14061196. PMID: 35335526; PMCID: PMC8955144. 2. Ikebe E, Matsuoka S, Tezuka K, Kuramitsu M, Okuma K, Nakashima M, Kobayashi S, Makiyama J, Yamagishi M, Oyadomari S, Uchimaru K, Hamaguchi I. Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells. Blood Adv. 2020 May 12;4(9):1845-1858. doi: 10.1182/bloodadvances.2019001139. PMID: 32369565; PMCID: PMC7218438.
In vivo protocol:
TBD
1: Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol. 2010 Sep;84(18):9210-6. doi: 10.1128/JVI.01164-10. Epub 2010 Jul 7. PubMed PMID: 20610719; PubMed Central PMCID: PMC2937597.